As Spark Therapeutics Inc.gears up to launch its gene therapy Luxturna (voretigene neparvovec) in the US, the big question is how much the company might charge for a one-time treatment that provides life-altering benefit to some patients with certain inherited forms of blindness. From CEO Jeffrey Marrazzo's comments during the company's third quarter earnings call Nov. 7, it seems the price could indeed be $1m or higher as some payers have feared.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?